LA
JOLLA, Calif., July 8, 2024
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium ("CRAC")
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer,
will present at two upcoming healthcare investment conferences:
- H.C. Wainwright 3rd Annual Kidney Virtual Conference on
Monday, July 15, 2024, at
11:00am ET/ 8:00am PT
- JonesTrading Healthcare Seaside Summit on Monday, July 15, 2024, at 1:15pm ET/ 10:15am
PT
Live webcasts of both presentations can be accessed in the
"Upcoming Events" section of CalciMedica's IR website at
https://ir.calcimedica.com/. A replay of the webcasts will be
archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved therapies. CalciMedica's lead
product candidate Auxora™ has demonstrated positive and consistent
clinical results in multiple completed efficacy clinical trials.
CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in AP with
SIRS and completed a Phase 2b trial
(called CARDEA –NCT04345614) in COVID pneumonia patients,
continues to support the ongoing Phase 1/2 AIPT study (called CRSPA
– NCT04195347), with data expected in 2025, and has initiated its
Phase 2 study (called KOURAGE – NCT06374797) in AKI with associated
AHRF with data expected in 2025. CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in
La Jolla, CA. For more
information, please visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-two-upcoming-healthcare-investment-conferences-302190742.html
SOURCE CalciMedica, Inc.